eligibility_summary
Eligibility: Adults (≥18) with consent, relapsed/refractory large B-cell lymphoma, ECOG ≤2 or KPS ≥60, planned commercial CAR-T within 3 months, ≤6 FDG-PET–avid sites treatable with ≤3 isocenters, measurable disease, recovered toxicities (≤grade 1), and WOCBP negative pregnancy test. Exclusions: prior CD19 therapy, RT <21 days, CNS disease, similar allergy, active diarrhea/infection or uncontrolled illness, other active cancer, pregnancy, or inability to comply/safety concerns.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Early phase I, single-arm study in relapsed/refractory large B‑cell lymphoma tests comprehensive bridging external beam radiation therapy (EBRT) to all FDG‑avid sites followed by commercial CD19‑directed CAR T‑cell infusion. Interventions: EBRT (ionizing radiation) to debulk/control disease by inducing DNA double‑strand breaks and tumor cell death, Biological: autologous, gene‑modified CAR T cells (adoptive cell therapy) that recognize CD19 on malignant B cells and trigger T‑cell activation/cytotoxicity, Procedures: leukapheresis, PET/CT, MRI, blood banking. Targets/pathways: CD19+ B‑cell lymphoma cells, CAR‑mediated T‑cell activation, radiation‑induced DNA damage/DDR pathways, potential tumor microenvironment modulation.